Skip to main
CRMD
CRMD logo

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. is projecting strong financial performance, with fourth-quarter net revenue expected between $115 million and $135 million, and full-year pro forma adjusted EBITDA guidance increased to $220 million to $240 million. The company has raised its full-year 2025 pro forma net revenue guidance to a range of $390 million to $410 million, largely due to the robust adoption of its product, DefenCath, and early contributions from the Melinta portfolio. Additionally, positive metrics from recent quarters, including a net revenue of $104.3 million in Q3 2025 driven by higher utilization of DefenCath among outpatient dialysis customers, reinforce the positive commercial execution narrative.

Bears say

Cormedix Inc faces a challenging outlook primarily due to the anticipated significant price drop of its product DefenCath following the second phase of the Transitional Drug Add-on Payment Adjustment (TDAPA) in July 2026. The company also risks underperforming in projected catheter lock solution sales, particularly as it competes against established generics like Heparin, which may impede revenue generation. Despite potential opportunities through its product Niyadas, the overshadowing uncertainties surrounding TDAPA pricing and competitive dynamics create a negative sentiment regarding the company's financial future.

CorMedix (CRMD) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 6 analysts, CorMedix (CRMD) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.